Novel aspects of Epithelial-Mesenchymal Transition(EMT)in pancreatic cancer

胰腺癌上皮间质转化（EMT）的新特点

• 批准号: 9042725
• 负责人: Murray Korc
• 金额: $ 5.48万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9042725
• 关键词: Apoptosis; Biological; Birth; CDKN2A gene; Cancer Cell Growth; Cell Count; Cell Line; Cell Proliferation; Cells; Collagen; Cyclin D1; Data; Development; Diagnosis; Diagnostic Neoplasm Staging; Disease; Drug Delivery Systems; ERBB2 gene; ERBB3 gene; Effectiveness; Epidermal Growth Factor Receptor; Epithelial; Exhibits; Family member; Fibroblasts; Frequencies; Functional disorder; Gene Targeting; Genetically Engineered Mouse; Growth; HER2 inhibition; Health; Hepatic; Heterogeneity; Human; Hypoxia; Immune; In Vitro; Incidence; Inflammatory; Injection of therapeutic agent; KRAS2 gene; Knowledge; Laboratories; Lesion; Ligands; Lung; MADH4 gene; Malignant Neoplasms; Malignant neoplasm of pancreas; Mediating; Mesenchymal; Metastatic Lesion; Metastatic Neoplasm to the Liver; Metastatic Neoplasm to the Lung; Mitogens; Modeling; Molecular; Molecular Profiling; Morbidity - disease rate; Mucins; Mus; Mutate; Mutation; Neoplasm Metastasis; Nuclear Translocation; Oncogenic; Pancreas; Pancreatic Ductal Adenocarcinoma; Pathway interactions; Patients; Phosphorylation; Proliferating; Protein Isoforms; Proto-Oncogene Proteins c-akt; Public Health; Publishing; Radiation therapy; Receptor Protein-Tyrosine Kinases; Resistance; Retinoblastoma Protein; Role; STAT3 gene; Signal Pathway; Signal Transduction; Staging; Study models; Survival Rate; TP53 gene; Testing; Therapeutic; Therapeutic Intervention; Transforming Growth Factor beta; Translating; Treatment Efficacy; Tumor stage; Untranslated RNA; Xenograft procedure; advanced disease; base; cancer cell; cancer stem cell; cell stroma; chemotherapy; cytokine; design; established cell line; gemcitabine; imaging system; improved; insight; intraepithelial; lapatinib; loss of function; mortality; mouse model; mutant; novel; overexpression; pancreatic cancer cells; prevent; protein expression; protein function; response; small hairpin RNA; tumor; tumor xenograft

DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with an overall 5-year survival rate of 6%. The molecular mechanisms that contribute to the biological aggressiveness of PDAC are being gradually elucidated, and the crucial role of high and low frequency driver mutations in PDAC is providing new insights into the complexity of this cancer. However, the widespread consequences of aberrant transforming growth factor-beta (TGF-beta) actions in PDAC in the context of the presence of oncogenic Kras and loss of function of the retinoblastoma protein are not well understood. In this proposal we will use a novel genetically engineered mouse model (GEM) of PDAC that we generated in which oncogenic Kras is combined with RB deletion. The resultant KRC mice rapidly develop pancreatic intraepithelial (PanIN) lesions that progress to PDAC within weeks after birth, and the pancreatic cancer cells in these cancers are highly proliferative. Based on our published data and preliminary results, the KRC mouse will allow us to test the hypothesis that aberrant TGF-beta signaling in PDAC synergizes with RB inactivation, leading to deleterious actions by TGF-beta, aberrant mitogenic signaling, and enhanced pancreatic cancer cell proliferation and cancer cell-stroma interactions. We will evaluate the effects of RB loss of function on TGF-beta signaling, assess the role of TGF-beta signaling in PDAC metastasis, and delineate the contributions of inflammatory cytokines and Wnt pathways to pancreatic cancer cell proliferation and stroma formation. To this end we will use cell lines established from KRC pancreata, use other novel GEMs of PDAC generated in our laboratory that exhibit a high incidence of metastases, conduct therapeutic interventions in these GEMs, and assess the role of these pathways in human PDAC. The proposed studies will advance our understanding of PDAC pathobiology in a high impact manner, and will point the way to novel therapies for suppressing cancer growth and metastasis.

描述（由申请人提供）：胰腺导管腺癌（PDAC）是一种致命的恶性肿瘤，总体5年生存率为6%。有助于PDAC生物侵袭性的分子机制正在逐步阐明，PDAC中高频和低频驱动突变的关键作用正在为这种癌症的复杂性提供新的见解。然而，在存在致癌Kras和视网膜母细胞瘤蛋白功能丧失的情况下，PDAC中异常转化生长因子-β（TGF-β）作用的广泛后果尚未得到充分理解。在这个建议中，我们将使用一种新的基因工程小鼠模型（GEM）的PDAC，我们产生的致癌Kras与RB删除相结合。由此产生的KRC小鼠迅速发展为胰腺上皮内（PanIN）病变，在出生后数周内进展为PDAC，并且这些癌症中的胰腺癌细胞具有高度增殖性。基于我们已发表的数据和初步结果，KRC小鼠将使我们能够测试PDAC中的异常TGF-β信号传导与RB失活协同作用的假设，从而导致TGF-β的有害作用、异常促有丝分裂信号传导以及增强的胰腺癌细胞增殖和癌细胞-基质相互作用。我们将评估RB功能丧失对TGF-β信号传导的影响，评估TGF-β信号传导在PDAC转移中的作用，并描述炎性细胞因子和Wnt通路对胰腺癌细胞增殖和基质形成的贡献。为此，我们将使用从KRC胰腺中建立的细胞系，使用我们实验室中产生的其他新的转移发生率高的PDAC GEM，在这些GEM中进行治疗干预，并评估这些途径在人类PDAC中的作用。拟议的研究将以高影响力的方式推进我们对PDAC病理生物学的理解，并将为抑制癌症生长和转移的新疗法指明方向。